Zobrazeno 1 - 10
of 41
pro vyhledávání: '"N. Segaud"'
Autor:
T. Pascart, P. Robinet, S. Ottaviani, R. Leroy, N. Segaud, A. Pacaud, A. Grandjean, H. Luraschi, T. Rabin, X. Deplanque, P. Maciejasz, F. Visade, A. Mackowiak, N. Baclet, A. Lefebvre, J.F. Budzik, T. Bardin, P. Richette, L. Norberciak, V. Ducoulombier, E. Houvenagel
Publikováno v:
Revue du Rhumatisme. 89:A19
Autor:
Chi Duc Nguyen, Nicolas Cohen, Bruno Fautrel, Jean-Hugues Salmon, Elisabeth Gervais, Guy Baudens, Céline Labadie, Eric Houvenagel, Maeva Kyheng, Pascal Richette, Isabelle Chary-Valckenaere, X. Deprez, Thao Pham, Pascal Claudepierre, Benoît Flachaire, René-Marc Flipo, Corinne Miceli-Richard, Philippe Dieudé, Peggy Philippe, Christophe Richez, Laurent Marguerie, Damien Loeuille, Pierre Lafforgue, Jérémie Sellam, N. Segaud, Jean-Guillaume Letarouilly, Florence Tubach, Marie-Hélène Guyot
Publikováno v:
Rheumatology
Rheumatology, Oxford University Press (OUP), 2021, 60 (6), pp.2773-2782. ⟨10.1093/rheumatology/keaa710⟩
Rheumatology, 2021, 60 (6), pp.2773-2782. ⟨10.1093/rheumatology/keaa710⟩
Rheumatology, Oxford University Press (OUP), 2021, 60 (6), pp.2773-2782. ⟨10.1093/rheumatology/keaa710⟩
Rheumatology, 2021, 60 (6), pp.2773-2782. ⟨10.1093/rheumatology/keaa710⟩
Objectives To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. Methods In this retrospective, national, multicentre cohort study, pt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ec649463308542556b4e73424d8943
https://hal.archives-ouvertes.fr/hal-03176959/document
https://hal.archives-ouvertes.fr/hal-03176959/document
Autor:
S Gally, Eric Houvenagel, Laurent Marguerie, René-Marc Flipo, X. Deprez, Nicolas Lecuyer, Jean-Paul Eschard, Isabelle Idier, Marie-Hélène Guyot, Jean Darloy, Guy Baudens, D Pau, Jean-Hugues Salmon, Vincent Goëb, N. Segaud
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 1, Pp 61-75 (2019)
Rheumatology and Therapy
Rheumatology and Therapy
Introduction The main objective of this work was to assess the maintenance of effectiveness of subcutaneous tocilizumab 6 months after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis (RA) in a real-world s
Autor:
Chi Duc Nguyen, Guy Baudens, Laurent Marguerie, Corinne Miceli Richard, Jérémie Sellam, René-Marc Flipo, Jean-Guillaume Letarouilly, J.H. Salmon, Julien Paccou, Pascal Richette, N. Segaud, Marie-Hélène Guyot, Maeva Kyheng, X. Deprez, Eric Houvenagel, Pascal Claudepierre, Philippe Dieudé, Elisabeth Gervais
Publikováno v:
Abstracts accepted for Publication.
Background Ustekinumab (UST) and secukinumab (SEK) are new Biologic Disease-modifying antiRheumatic Drugs (bDMARDs) available in psoriatic arthritis (PsA), targeting respectively IL12-23 and IL 17. Real-world data are missing for these drugs, despite
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Philippe Dieudé, N. Segaud, Chi Duc Nguyen, Thao Pham, P. Claudepierre, C. Miceli Richard, Maeva Kyheng, B. Flachaire, X. Deprez, I. Chary Valckenaere, Damien Loeuille, R.M. Flipo, P. Lafforgue, Bruno Fautrel, Christophe Richez, Laurent Marguerie, Eric Houvenagel, J.H. Salmon, Jérémie Sellam, Elisabeth Gervais, F. Maury, Nicolas Cohen, J. G. Letarouilly, C. Labadie, P. Richette, Marie-Hélène Guyot, Guy Baudens
Publikováno v:
Annals of the Rheumatic Diseases. 79:769.2-769
Background:Real-world data are missing for Ustekinumab (UST) and secukinumab (SEK) in psoriatic arthritis (PsA).Objectives:To evaluate the characteristics of the patients (pts) with PsA treated by UST or SEK and to assess real world persistence of US
Autor:
J.H. Salmon, C. Chopin, Guy Baudens, Marie-Hélène Guyot, Vincent Goëb, S Gally, Isabelle Idier, R.M. Flipo, J. Darloy, Laurent Marguerie, N. Segaud
Publikováno v:
Rheumatoid arthritis – biological DMARDs.
Background It has been proven, in a pivotal RCT, that SC tocilizumab (TCZ) was non-inferior to IV TCZ.1 However the switch from IV to SC TCZ has not been evaluated to date in a large real-world study. Objectives The main objective was to assess the m
Publikováno v:
Value in Health. 22:S589-S590
Publikováno v:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 29(5)
In renal transplant patients, bone loss may be related to the drugs patients are taking but also to their past history of chronic kidney disease. The purpose of this study was to assess changes in BMD 2 years after an initial assessment (performed 9